Cardiovascular disease remains the greatest cause of premature death worldwide and about 50% of deaths occur in Asia. 1 Asian populations have a higher proportion of stroke deaths than the rest of the world, which requires special attention. 2 The United Nations Sustainable Development Goals contain a specific noncommunicable disease (NCD) target to reduce premature mortality from chronic diseases by one third by 2030. At present, it is estimated that annually 15 million people (4.5 million in Asia-Pacific Academic Consortium for Public Health [APACPH] countries) between the ages of 30 and 69 years die from a NCD and the large majority are from cardiovascular causes. 3 In APACPH countries, the total number of deaths has increased in the past 3 decades with increasing population; and the proportion of deaths due to chronic diseases has increased from 66% to 85%. In most of our APACPH countries, the age-adjusted mortality rates are higher than Western countries: the exceptions being Japan, South Korea, Singapore, and Thailand. 1 At present, Japan has the lowest coronary heart disease (CHD) mortality rate in the world. Between 1980 and 2012, age-adjusted CHD mortality rates in Japan fell by 60% for males and 62% for females. There were 75 700 fewer CHD deaths in 2012 in Japan than if the age-and sexspecific mortality rates had remained unchanged. 4 Australia had experienced a similar decline, but it began several decades earlier. From 1976 to 2006, the overall age-adjusted mortality rate for CHD declined by 73% in men and 70% in women. 5 Other Western countries have experienced similar trends. However, the annual morbidity and mortality burden of CHD remains one of the greatest challenges for public health.
estimates the following worldwide deaths occur annually from chronic diseases due to the major risk factors 3 :
• • Tobacco-7.2 million deaths (including from exposure to secondhand smoke) • • Excess salt/sodium intake-4.1 million deaths • • Alcohol-1.65 million deaths from NCDs, including cancer • • Insufficient physical activity-1. 6 
million deaths
The World Health Organization has suggested 6 "best buys" to address the global epidemic of NCDs. Implementing the "best buys" will reduce premature mortality by 15% by 2030 and prevent over 17 million cases of ischemic heart disease and stroke in low-and medium-income countries (LMICs). 6 The 6 "best buys," most of which would reduce heart disease, are the following: While the traditional emphasis of public health has always been on prevention, we are faced with several generations of heart patients who are already with us and require treatment as well as preventive services. Secondary prevention with medications can substantially improve disability-free survival. In the PURE (Prospective Urban Rural Epidemiology) study, it was found that in LMICs, 80% of patients with cardiovascular diseases in LICs compared with 11% in highincome countries did not receive any of the 4 priority cardiovascular disease medications. There can also be wide differences in access to primary and secondary treatments within countries. 8, 9 Heart disease and stroke morbidity and mortality can be reduced with appropriate preventive treatment, and the "polypill," a mixture of basic medications for hypertension and hyperlipidemia, has been shown to be effective. 10, 11 The cost of multiple drug treatment with a "polypill" would be affordable in most of the APACPH countries. A modelling study in South Africa found that the pharmacologic interventions would be cost-effective due to health gains and cost savings from prevented hospital admissions and chronic disease complications. 12 The use of a single "polypill" reduces pill burden and improves compliance. The high rate of smartphone use in Asia provides a promising tool for chronic disease management, for example, through monitoring of treatment compliance.
Most of the countries in the Asia Pacific region provide some treatments for acute CHD and stroke patients. With the high rate of cardiovascular diseases, the potential demand for diagnostic and interventional cardiology is almost unlimited. Zilla and colleagues estimated that more than 6 billion people who live outside industrialized countries did not have sufficient access to cardiac surgery. 13 In line with other groups advocating interventional services, they documented a need, but omitted any discussion of the opportunity costs if this becomes a health service priority.
Physicians (and politicians) everywhere have a fascination with the latest in high-technology cardiology and always advocate for its availability. The cost of these services is high, and in many countries, it is unaffordable to all but the wealthiest. In many cases, the private sector or treatment in private hospitals ends up being subsidized by the government as there is a demand for interventional services from public servants, politicians, military, and so on.
Does the provision of high-level services for the rich exclude mid-level services for the rest of the population and therefore increase health inequity? Should we wait until a country can afford to offer cardiac stenting or valve replacement to the whole country, including rural areas, before anyone is allowed to access it in-country. The answer is not simple. Physicians trained to conduct interventional cardiology will feel frustrated if unable to exercise their skills and perhaps migrate to wealthier countries. International medical device companies may advertise and try to influence opinion. A massive global industry has developed in the past 40 years since stenting was first introduced. In 2017, the global stent market was estimated to be $7.2 billion, and in South Korea, the cost was around $159 million. 14 Capital city media may run campaigns seeking services to bring their countries into the 21st century, ignoring the provision of basic universal services. Equity in health services access and indeed in health can be an elusive goal.
Faced with the increasing epidemic of cardiovascular diseases, the public health response first involves population-based prevention programs centered on nutrition, exercise, and obesity control. At the next level for those with established diseases or in a high-risk category, to supplement primary prevention they could be offered medical intervention (a "polypill"). The final level of response, the introduction of interventional cardiology, remains problematic for LMICs because of costs. Choosing an appropriate mix of these services to benefit the maximum number of our citizens is a complex task, but an essential one for Schools of Public Health to engage it. The journal welcomes contribution to this debate through letters to the editor, short commentaries, or longer reviews.
